Clinical Trial Update: DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of DTGM Fusion Protein in patients with recurrent or refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DTGM Fusion Protein

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED